VolitionRX Revolutionizes Pet Cancer Diagnosis with Automated Nu.Q® Vet Cancer Test

VolitionRX Enhances Pet Cancer Diagnostics with Automated Testing Solution

VolitionRX Limited, a leader in epigenetic diagnostics, has made significant strides in veterinary medicine through the recent validation and verification of its chemiluminescent immunoassay (ChLIA) version of the Nu.Q® Vet Cancer Test. In collaboration with Fujifilm Vet Systems Co. Ltd., this development enables full automation in central laboratories, marking a pivotal move from the traditional manual testing methods that have characterized veterinary diagnostics. This innovation not only improves efficiency but also elevates the reliability and scalability of cancer screening for canines, a pressing need in Japan where cancer is the leading cause of death among adult dogs.

The implementation of the Nu.Q® Vet Cancer Test comes at a critical time, as more than 1,700 veterinary hospitals in Japan have registered to utilize this advanced diagnostic tool since its launch in July 2024. With approximately seven million pet dogs in the country, early detection of cancer becomes essential for improving survival rates and treatment outcomes. Fujifilm Vet Systems' President, Junichi Makino, expresses enthusiasm about the strong demand for the Nu.Q® Vet Cancer Test, underscoring its vital role in providing accessible and affordable cancer screening options for pet owners. This shift towards automated testing aligns with the growing emphasis on precision veterinary medicine, amplifying the test's impact within the market.

Dr. Jasmine Kway, CEO of Singapore Volition, notes the partnership with Fujifilm Vet Systems holds significant revenue potential, given the latter's prominence as a diagnostic provider in Japan. The Nu.Q® Vet Cancer Test incorporates technology from the Immunodiagnostic Systems (IDS) i10® platform, which mirrors Volition’s human cancer diagnostics, thereby demonstrating a cross-species application of their innovative academic research. This strategic collaboration not only reinforces their commitment to enhance health outcomes through epigenetics but also solidifies Volition's standing in Japan's expansive veterinary diagnostic market, providing pet owners with timely and effective cancer screening resources.

In addition to its technical advancements, VolitionRX’s automated platform represents a substantial step towards improving veterinary care, aligning with the increasing awareness about pet health and preventive treatments. By harnessing breakthrough diagnostics, the company aims to facilitate quicker interventions for cancer in dogs, ultimately supporting a healthier pet population.

As the company continues to expand its efforts in the veterinary sector, the success of the Nu.Q® Vet Cancer Test sets a precedent for future innovations in both animal and human health diagnostics, emphasizing the potential for cross-disciplinary applications of their epigenetic technology.